171.86
Precedente Chiudi:
$170.98
Aprire:
$171.22
Volume 24 ore:
1.52M
Relative Volume:
1.12
Capitalizzazione di mercato:
$22.56B
Reddito:
$1.53B
Utile/perdita netta:
$-214.69M
Rapporto P/E:
-97.65
EPS:
-1.76
Flusso di cassa netto:
$-43.68M
1 W Prestazione:
+3.94%
1M Prestazione:
+11.21%
6M Prestazione:
+6.17%
1 anno Prestazione:
+60.32%
Natera Inc Stock (NTRA) Company Profile
Nome
Natera Inc
Settore
Industria
Telefono
650-249-9090
Indirizzo
13011 MCCALLEN PASS, AUSTIN, CA
Confronta NTRA con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
NTRA
Natera Inc
|
171.86 | 22.56B | 1.53B | -214.69M | -43.68M | -1.76 |
![]()
TMO
Thermo Fisher Scientific Inc
|
397.88 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
196.39 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
523.92 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
115.56 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
154.73 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-13 | Iniziato | RBC Capital Mkts | Outperform |
2025-01-23 | Iniziato | Barclays | Overweight |
2024-06-03 | Ripresa | Jefferies | Buy |
2024-04-08 | Ripresa | Craig Hallum | Buy |
2024-02-20 | Downgrade | Raymond James | Strong Buy → Outperform |
2023-12-29 | Reiterato | BTIG Research | Buy |
2023-12-14 | Iniziato | Guggenheim | Buy |
2023-12-13 | Iniziato | Wolfe Research | Outperform |
2023-11-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
2023-09-28 | Iniziato | Bernstein | Mkt Perform |
2023-07-05 | Ripresa | JP Morgan | Overweight |
2023-05-05 | Iniziato | UBS | Buy |
2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
2022-08-25 | Iniziato | Credit Suisse | Outperform |
2022-04-25 | Iniziato | Stephens | Overweight |
2022-03-08 | Iniziato | Goldman | Buy |
2022-01-06 | Ripresa | Piper Sandler | Overweight |
2021-10-15 | Ripresa | Cowen | Outperform |
2021-06-15 | Iniziato | Raymond James | Mkt Perform |
2021-05-25 | Iniziato | Wells Fargo | Overweight |
2021-01-28 | Iniziato | Truist | Buy |
2020-10-08 | Iniziato | BTIG Research | Buy |
2020-09-28 | Iniziato | Morgan Stanley | Overweight |
2020-09-17 | Iniziato | SVB Leerink | Outperform |
2020-06-10 | Ripresa | Piper Sandler | Overweight |
2020-05-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
2018-10-05 | Iniziato | JP Morgan | Neutral |
2018-07-05 | Reiterato | Piper Jaffray | Overweight |
2017-08-07 | Reiterato | Morgan Stanley | Overweight |
2016-11-10 | Reiterato | The Benchmark Company | Buy |
2016-05-23 | Reiterato | The Benchmark Company | Buy |
2016-05-11 | Reiterato | The Benchmark Company | Buy |
2016-04-19 | Iniziato | The Benchmark Company | Buy |
2015-09-28 | Aggiornamento | Wedbush | Neutral → Outperform |
2015-08-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2015-08-04 | Iniziato | Robert W. Baird | Outperform |
2015-07-27 | Iniziato | Morgan Stanley | Equal-Weight |
2015-07-27 | Iniziato | Piper Jaffray | Overweight |
2015-07-27 | Iniziato | Wedbush | Neutral |
Mostra tutto
Natera Inc Borsa (NTRA) Ultime notizie
Natera Approves Equity Plan Amendment at Annual Meeting - TipRanks
DNA Testing Market Size, Share, and Forecast 2025-2033: Key - openPR.com
Natera: Growth Likely To Moderate, Despite Signatera Test Medicare Coverage (NASDAQ:NTRA) - Seeking Alpha
Non-Invasive Cancer Testing Market Forecast | Major Players: Guardant Health, Exact Sciences, Qiagen, Natera Inc. - openPR.com
Where are the Opportunities in (NTRA) - news.stocktradersdaily.com
Here's How Much You Would Have Made Owning Natera Stock In The Last 10 Years - Benzinga
Insider Sell: Gail Marcus Sells 4,000 Shares of Natera Inc (NTRA) - GuruFocus
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase - Yahoo Finance
Transcript : Natera, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02 - MarketScreener
Prenatal Genetic Counselling Market 2025-2032: Top Trends & - openPR.com
Natera at Goldman Sachs Conference: Strategic Growth and Expansion - Investing.com Australia
Natera at Goldman Sachs Conference: Strategic Growth and Expansion By Investing.com - Investing.com India
Insider Sell: Steven Chapman Sells Shares of Natera Inc (NTRA) - GuruFocus
Colorectal Cancer Diagnostics Market Size To Boom with Top Key - openPR.com
Natera stock gains after Leerink Partners reiterates outperform rating By Investing.com - Investing.com South Africa
Natera's Signatera test to be covered under Medicare - MSN
Medicare expands coverage for Natera’s Signatera MRD test By Investing.com - Investing.com South Africa
Sector Update: Health Care - marketscreener.com
Natera Inc (NTRA) Trading 4.28% Higher on Jun 4 - GuruFocus
Natera (NTRA) Gains Medicare Coverage for Genome-Based Cancer Te - GuruFocus
Natera stock gains after Leerink Partners reiterates outperform rating - Investing.com
Natera's Signatera test to be covered under Medicare (NTRA:NASDAQ) - Seeking Alpha
Natera, Inc. Announces Medicare Coverage for Signatera Genome - marketscreener.com
Natera (NTRA) Secures Medicare Coverage for Signatera MRD Assay | NTRA Stock News - GuruFocus
Natera announces Medicare coverage for Signatera MRD assay - TipRanks
Medicare expands coverage for Natera’s Signatera MRD test - Investing.com Australia
Natera Announces Medicare Coverage for Signatera™ Genome | NTRA Stock News - GuruFocus
Natera Announces Medicare Coverage for Signatera ™ Genome - Business Wire
Natera Announces Medicare Coverage for Signatera™ Genome - New Castle News
Natera (NasdaqGS:NTRA) Showcases 94% Sensitivity In Pan-Cancer Signatera Genome Study - simplywall.st
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025 - GuruFocus
Natera Inc.: Is The Recent Growth in Signatera Volumes Here To Stay? - Smartkarma
Natera Inc (NTRA) Shares Up 3.07% on May 27 - GuruFocus
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Benzinga
When the Price of (NTRA) Talks, People Listen - news.stocktradersdaily.com
Natera Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting | NTRA Stock News - GuruFocus
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting - Yahoo Finance
Natera raises 2025 revenue outlook to $1.94B-$2.02B with 26% growth target - MSN
Transcript : Natera, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2025, May-21-2025 10 - marketscreener.com
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Stocks Showing Rising Market Leadership: Natera Earns 82 RS Rating - Investor's Business Daily
There's Reason For Concern Over Natera, Inc.'s (NASDAQ:NTRA) Price - simplywall.st
Natera (NASDAQ:NTRA) Rating Lowered to “Sell” at StockNews.com - Defense World
Natera (NASDAQ:NTRA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Natera: The Clues In Q1 Earnings (NASDAQ:NTRA) - Seeking Alpha
NTRA: Piper Sandler Raises Price Target for Natera | NTRA Stock News - GuruFocus
Natera Inc Azioni (NTRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Natera Inc Azioni (NTRA) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
May 28 '25 |
Sale |
161.00 |
10,000 |
1,610,000 |
35,000 |
Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
May 20 '25 |
Sale |
153.90 |
10,000 |
1,539,000 |
45,000 |
Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
May 15 '25 |
Sale |
150.20 |
10,000 |
1,502,000 |
74,000 |
Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Jun 13 '25 |
Sale |
165.85 |
5,000 |
829,250 |
30,000 |
Sheena Jonathan | CO-FOUNDER |
Jun 18 '25 |
Sale |
167.29 |
3,070 |
513,571 |
248,774 |
Sheena Jonathan | CO-FOUNDER |
Jun 16 '25 |
Sale |
164.55 |
3,000 |
493,649 |
37,282 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):